Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Visit V6_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-Nr.2012-004916-79 - Visit V6 (Day 196 + - 14)

- 27.09.21 - 1 Formular, 5 Itemgruppen, 35 Datenelemente, 1 Sprache

Itemgruppen: Visit, Physical examination, Medical Examination Rhinoscope, Spirometry; Peak Expiratory Flow, medication Demand

Study part: Visit V6 (Day 196 + - 14). Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Vital Signs Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Vital Signs Follow- Up (Visit 10)

- 27.09.21 - 1 Formular, 1 Itemgruppe, 10 Datenelemente, 1 Sprache

Itemgruppe: Vital Signs

Study Part: Vital Signs Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Visite 8 (Woche 24) TMP001 Multiple Sclerosis NCT02686788 - Visite 8 (Woche 24)

- 27.09.21 - 1 Formular, 11 Itemgruppen, 57 Datenelemente, 1 Sprache

Itemgruppen: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug

Study part: Visite 8 (Woche 24). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 7 (Woche 20) TMP001 Multiple Sclerosis NCT02686788 - Visite 7 (Woche 20)

- 27.09.21 - 1 Formular, 11 Itemgruppen, 57 Datenelemente, 1 Sprache

Itemgruppen: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug

Study part: Visite 7 (Woche 20). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Baseline Visite (Visite 2/ Woche 0) TMP001 Multiple Sclerosis NCT02686788 - Baseline Visite (Visite 2/ Woche 0)

- 27.09.21 - 1 Formular, 10 Itemgruppen, 53 Datenelemente, 1 Sprache

Itemgruppen: Administrative documentation, Vital signs; Body Temperature, Comorbidity; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Inclusion criteria; exclusion criteria, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug

Study part: Baseline Visite (Visite 2/ Woche 0). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 5 (Woche 12) TMP001 Multiple Sclerosis NCT02686788 - Visite 5 (Woche 12)

- 27.09.21 - 1 Formular, 11 Itemgruppen, 57 Datenelemente, 1 Sprache

Itemgruppen: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug

Study part: Visite 5 (Woche 12). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 6 (Woche 16) TMP001 Multiple Sclerosis NCT02686788 - Visite 6 (Woche 16)

- 27.09.21 - 1 Formular, 11 Itemgruppen, 57 Datenelemente, 1 Sprache

Itemgruppen: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug

Study part: Visite 6 (Woche 16). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 3 (Woche 4) TMP001 Multiple Sclerosis NCT02686788 - Visite 3 (Woche 4)

- 27.09.21 - 1 Formular, 11 Itemgruppen, 57 Datenelemente, 1 Sprache

Itemgruppen: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug

Study part: Visite 3 (Woche 4). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 4 (Woche 8) TMP001 Multiple Sclerosis NCT02686788 - Visite 4 (Woche 8)

- 27.09.21 - 1 Formular, 11 Itemgruppen, 57 Datenelemente, 1 Sprache

Itemgruppen: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug

Study part: Visite 4 (Woche 8). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.